Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model

Journal of Clinical Investigation

Volumn 97, Issue 7, 1996, Pages 1630-1639

  Shih, Diana M ^a   Gu, Lingjie ^a   Hama, Susan ^b   Xia, Yu Rong ^a   Navab, Mohamad ^b   Fogelman, Alan M ^b   Lusis, Aldons J ^a,b  

^a Pacific Hall   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diet; high density lipoproteins; inbred strains; lipoprotein oxidation; monocytes

Indexed keywords

ARYLESTERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CONTROLLED STUDY; DIET; GENE EXPRESSION REGULATION; GENETIC REGULATION; LIPID OXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

EID: 0029918732     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118589     Document Type: Article

References (46)

1. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. Variation in susceptibility Lo atherosclerosis among inbred strains of mice. Atherosclerosis. 57:65-73.
2. Paigen, B., D. Mitchell, K. Reue, R. Morrow, A.J. Lusis, and R C. LeBoeuf. 1987. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc. Natl. Acad Sci USA. 84:3763-3767.
3. Parthasarathy, S., D. Steinberg, and J.L. Witztum. 1992. The role of oxidized low-density lipoproteins in the pathogenesis atherosclerosis. Annu. Rev. Med. 43:219-225.
4. Berliner, J.A., M. Navab, A.M. Fogelman. J.S. Frank, L.L Demer, P.A. Edwards, A D. Watson, and A.J. Lusis. 1995. Atherosclerosis: basic mechanisms, oxidation, inflammation, and genetics. Circulation. 91:2488-2496.
5. Liao, F., A. Andalibi, F.C. deBeer, A.M. Fogelman, and A.J. Lusis. 1993. Genetic control of inflammatory gene induction and NF-κB-like transcription factor activation in response to an atherogenic diet in mice. J. Clin. Invest. 91: 2572-2579.
6. Liao, F , J.A. Berliner, M Mehrabian, M. Navab, L.L. Demer, A.J. Lusis, and A.M. Fogelman. 1991. Minimally modified low density lipoprotein is biologically active in vivo in mice. J. Clin. Invest. 87:2253-2257.
7. Rosenfeld, M.E., S. Yla-Herttuala, B.A Lipton, V A. Ord, J.L Witztum, and D. Steinberg. 1992. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesion of rabbits and humans. Am. J. Pathol. 140:291-300.
8. Yla-Herttuala, S., B.A. Lipton, M.E. Rosenfeld, T. Sarkioja, T. Yoshimura, E.J. Leonard, J.L. Witztum, and D. Steinberg 1991. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad Sci. USA 88:5252-5256.
9. Navab, M , S.S. Imes, S.Y. Hama, G.P. Hough, L.A. Ross, R W. Bork, A.J. Valente, J.A. Berliner, D.C. Drinkwater, H. Laks, and A.M. Fogelman. 1991. Monocyte transmigration induced by modification of low density lipoprotein in coculture of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J. Clin. Invest. 88.2039-2046.
10. Stafforini, D.M., G.A. Zimmerman, T.M. McIntyre, and S.M. Prescott. 1992. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc. Am. Physicians. 105:44-63
11. Watson, A D., M. Navab, S.Y. Hama, A. Sevanian, S M. Prescott, D.M. Stafforini. T.M. McIntyre, B.N. Du, A M. Fogelman, and J.A. Berliner. 1995. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J. Clin. Invest. 95:774-782.
12. Watson, A.D., J.A Berliner, S.Y. Hama, B.N La Du, K.F. Faull, A M. Fogelman, and M. Navab. 1995. Protective effect of HDL associated paraoxanase-inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96.2882-2891.
13. Havel, R J., H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins of human serum. J. Clin. Invest. 43:1345 1353.
14. Gan, K.N., A. Smolen, H.W. Eckerson, and B.N. La Du. 1991 Purification of human serum paraoxonase/arylesterase Evidence for one esterase catalyzing both activities. Drug Metab Dispos. 19:100-106.
15. Warden, C.H., J.H. Qiao, L.W. Castellani, and A.J. Lusis. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science (Wash DC). 263:469-472.
16. Doolittle, M.H , R.C. LeBoeuf. C.H. Warden L M. Bee, and A.J. Lusis. 1990. A polymorphism affecting apolipoprotein A-II translational efficiency determines high density lipoprotein size and composition. J. Biol. Chem. 265, 16380-16388.
17. LeBoeuf, R.C., M.H. Doolittle, A Montcalm, D.C. Martin, K. Reue, and A.J. Lusis. 1990. Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. J. Lipid Res. 31:91-101.
18. Navab, M., G.P. Hough, L.W Stevenson. D.C Drinkwater, H. Laks, and A M. Fogelman 1988 Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J. Clin Invest. 82:1853-1863
19. Hassett, C, R.J. Richter, R. Humbert, C. Chapline, J.W Crabb, C J Omiecinski, and C.E Furlong. 1991. Characterization of cDNA clones encoding rabbit and human serum paraoxonasc: the mature protein retains its signal sequence. Biochemistry 30:10141-10149.
20. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem 162.156-159.
21. Liao, F., A. Andalibi, J.-H. Qiao, H. Allayee, A.M. Fogelman, and A.J Lusis. 1994. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice J Clin. Invest. 94:877-884.
22. Warden, C.H., M Mehrabian, K.-Y. He, M Y. Yoon. A. Diep, Y.-R. Xia, P Z Wen, K.L. Svenson, R.S. Sparkes. and A.J. Lusis. 1993. Linkage mapping of 40 randomly isolated liver cDNA clones in the mouse. Genomics 18: 295-307.
23. Mackness, M.I., S. Arrol, and P.N. Durrington. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286: 152-154.
24. Mackness, M.I., S. Arrol, C. Abbott, and P.N. Durrington. 1993. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 104:129-135.
25. Blatter, M.-C., R. W. James, S. Mcssmer, F. Barja, and D. Pometta. 1993. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 211:871-879.
26. Saha, N., A C. Roy, S.H. Teo, J.S.H. Tay, and S.S. Ratnam 1991. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin. Genet. 40:277-282.
27. Garin, M.-C.B., C. Abbott, S. Messmer, M. Mackness, P. Durrington, D. Pometta, and R W. James. 1994. Quantitation of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations Biochem. J. 304:549-554.
28. Humbert, R., D.A Adler, C.M. Disteche, C. Hassett, C.J. Omiecinski, and C.E. Furlong. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:73-76.
29. Mehrabian, M , J.-H. Qiao, R. Hyman, D. Ruddle, C. Laughton, and A.J. Lusis. 1993. Influence of the ApoA-II gene locus on HDL levels and fatty streak development in mice. Arterioscler Throtnb. 13:1-10.
30. Brealey, C.J., C.H. Walker, and B.C. Baldwin. 1980. A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. Pestic Sci. 11.546-554.
31. La Du, B.N. 1992. Human serum paraoxonase/arylesterase. In Pharmacogenetics of Drug Metabolism. W Katow, editor. Pergamon Press, Inc., New York, 51-91.
32. Tall, A. 1990. Plasma high density lipoproteins metabolism and relationship to atherogenesis J. Clin Invest 86:379-384.
33. Eggesbo, J B , I Hjermann, P.K. Lund, G B. Joo, R. Ovstebo, and P Kierulf. 1994. LPS-induced release of IL-1 beta, IL-6, IL-8, TNF-alpha and sCD14 in whole blood and PBMC from persons with high or low levels of HDL-lipoprotein Cytokine. 6:521-529.
34. Wurfel, M.M., S.T. Kunitake. H. Lichenstein, J.P. Kane, and S.D Wright. 1994. Lipopolysacchande (LPS) -binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp Med. 180:1025-1035.
35. Flegel, W A., M.W. Baumstark, C. Weinstock, A. Berg, and H Northoff. 1993. Prevention of endotoxin induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect. Immun 61:5140-5146.
36. Baumberger, C., R J, Ulevitch, and J.M Dayer. 1991. Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology 59:378-383.
37. Vosbeck, K., P. Tobias, H Muller, R.A. Allen, K E. Arfors, R.J Ulevitch, and L.A. Sklar. 1990. Priming of polymorphonuclear granulocyles by lipopolysaccharides and its complexes with lipopolysaccharide binding protein and high density lipoprotein. J. Leuk Biol. 47:97-104.
38. Parthasarathy, S., J. Barnett, and L G. Fong. 1990. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta 1044:275-283.
39. Bowry, V.W . K.K Stanley, and R. Stocker. 1992. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc. Natl Acad Sci. USA 89:10316-10320.
40. Patel, B.N., M.I. Mackness, D.W. Harty, S. Arrol, R.P. Boot-Handford, and P.N. Durrington. 1990. Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. Biochem. Biophys. Acta. 1035:113-116
41. Playfer, J.R., L.C. Eze, M F. Bullen, and D.A.P. Evans. 1976. Genetic polymorphism and interethnic variability of plasma paraoxonase activity. J Med. Genet. 13:337-342.
42. Adkins, S., K.N. Gan, M. Mody, and B.N. La Du.1993. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glulamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet. 52:598-608.
43. McElveen, J., M.I. Mackness, C.M. Colley, T. Peard, S. Warner, and C.H. Walker. 1986 Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infaction. Clin. Chem. 32:671-673.
44. Mackness, M.I., D. Harty, D. Bhatnagar, P.H. Winocour, S. Arrol, M Ishola, and P.N. Durrington. 1991. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 86:193-199.
45. Pavkovic, E., V. Simeon, E. Reiner, M. Sucic, and V. Lipovac. 1993. Serum paraoxonase and cholinesterase activities in individuals with lipid and glucose metabolism disorders. Chem. Biol. Interact. 87:179-182.
46. Hegele, R.A., J.H. Brunt, and P.W. Connelly. 1995. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler. Thromb. Vasc. Biol 15:89-95.